Locally Advanced BCC

Patient Case
Studies

In a study of patients with laBCC previously treated with an HHI1

Clinically meaningful tumor reduction observed after treatment with LIBTAYO1,2

Patient responses

The objective response rate in Study 1620 was 29% of patients with laBCC. Median DOR was not reached (2.1-21.4+ months)1

These are examples from the 23% of patients who had a PR in Study 1620.1 Individual patient responses may vary.

Right auricular lesion

Right auricular
lesion


Screening

Auricular lesion, screening image

After 18 weeks

Auricular lesion, after 18 weeks image

After 81 weeks

Auricular lesion, after 81 weeks image

After 104 weeks

Auricular lesion, after 104 weeks image

Actual clinical trial patient

History2

  • 79-year-old man
  • Locally advanced BCC
  • Disease progression on prior vismodegib

Clinical outcomes

(as of data cutoff February 17, 2020)2

  • Best overall response: PR by composite evaluation (RECIST 1.1 + WHO criteria) per ICR
  • Time to response: 4.2 months
  • Duration of response: 19.7+ months
Right cranial lesion

Right cranial lesion


Screening

Cranial lesion, screening image

After 9 weeks

Cranial lesion, after 9 weeks image

After 18 weeks

Cranial lesion, after 18 weeks image

After 101 weeks

Cranial lesion, after 101 weeks image

Actual clinical trial patient

History2

  • 66-year-old man
  • Locally advanced BCC
  • Intolerance on prior vismodegib

Clinical outcomes

(as of data cutoff February 17, 2020)2

  • Best overall response: PR by composite evaluation (RECIST 1.1 + WHO criteria) per ICR
  • Time to response: 4.2 months
  • Duration of response: 19.1+ months
Right nasal cavity lesion

Right nasal cavity lesion


Screening

Nasal cavity lesion, screening image

After 36 weeks

Nasal cavity lesion, after 36 weeks image

After 44 weeks

Nasal cavity lesion, after 44 weeks image

After 92 weeks

Nasal cavity lesion, after 92 weeks image

Actual clinical trial patient

History2

  • 77-year-old woman
  • Locally advanced BCC
  • Disease progression on prior vismodegib

Clinical outcomes

(as of data cutoff February 17, 2020)2

  • Best overall response: PR by composite evaluation (RECIST 1.1 + WHO criteria) per ICR
  • Time to response: 8.2 months
  • Duration of response: 4.8 months

The duration of response for this patient was 4.8 months. At the time of data cutoff, this patient was no longer in response due to having progressive disease.

This is an example from the 6% of patients who had a CR in Study 1620.1 Individual patient responses may vary.

Left periorbital lesion

Left periorbital
lesion

Screening

Periorbital lesion, screening image

After 18 weeks

Periorbital lesion, after 18 weeks image

After 45 weeks

Periorbital lesion, after 45 weeks image

After 68 weeks

Periorbital lesion, after 68 weeks image

Actual clinical trial patient

History2

  • 49-year-old man
  • Locally advanced BCC
  • Disease progression on prior vismodegib

Clinical outcomes

(as of data cutoff February 17, 2020)2

  • Best overall response: PR by composite evaluation (RECIST 1.1 + WHO criteria) per ICR
  • Time to response: 4.2 months
  • Duration of response: 11.5+ months
  • Plus sign (+) denotes ongoing at last assessment.1
  • BCC=basal cell carcinoma; CR=complete response; DOR=duration of response; HHI=hedgehog pathway inhibitor; ICR=independent central review; laBCC=locally advanced BCC; PR=partial response; RECIST=Response Evaluation Criteria in Solid Tumors; WHO=World Health Organization.